Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down After Earnings Miss

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)’s stock price gapped down before the market opened on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $108.62, but opened at $96.53. Mirum Pharmaceuticals shares last traded at $94.9690, with a volume of 253,699 shares.

The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The business had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.98% and a negative net margin of 4.48%.The company’s quarterly revenue was up 49.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.00 earnings per share.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue beat and strong product growth—Mirum posted ~50% y/y revenue growth driven by Livmarli and other bile-acid therapies, beating Street revenue estimates, which supports the company’s top-line trajectory. Article Title
• Positive Sentiment: Corporate release and call provide detail and FY revenue guide—Mirum’s press release and earnings call outlined operations and gave FY2026 revenue guidance ($630M–$650M), offering a revenue roadmap for investors even as EPS guidance/detail was limited. Article Title
• Positive Sentiment: Analysts largely remain bullish — multiple firms raised or reiterated positive ratings and targets (TD Cowen, Stifel Nicolaus, RBC and others continue to show upside vs. the current price), signaling analyst confidence in longer-term upside despite short-term noise. Article Title
• Neutral Sentiment: Transcripts and analysis available—Earnings-call transcripts and analyst writeups (Seeking Alpha, The Motley Fool, Zacks) give more color for investors deciding whether the EPS miss is a one-off or structural. Use these to dig into margins, SG&A, and commercial execution details. Article Title Article Title
• Negative Sentiment: EPS miss and margin concerns—Mirum reported ($0.11) EPS vs. a ~$0.02 consensus, a significant miss that triggered the selloff despite the revenue beat; investors are focused on margins, profitability timeline, and whether EPS guidance will be conservative. Article Title
• Negative Sentiment: Immediate market reaction and volume—Coverage and commentary (AAII and others) point to the EPS miss + any perceived conservative guidance as the proximate cause of today’s decline; heavy volume suggests short-term technical selling even as analysts debate the longer-term story. Article Title

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MIRM shares. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Evercore reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Citizens Jmp decreased their price objective on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $114.92.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 1,421 shares of the stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $132,621.93. Following the completion of the transaction, the chief financial officer directly owned 42,127 shares in the company, valued at approximately $3,931,712.91. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the transaction, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. The trade was a 5.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,136 shares of company stock worth $4,352,029 over the last 90 days. Insiders own 14.36% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. purchased a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. MCF Advisors LLC lifted its holdings in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth about $33,000.

Mirum Pharmaceuticals Price Performance

The stock has a market capitalization of $4.74 billion, a P/E ratio of -192.06 and a beta of 0.49. The firm has a fifty day moving average price of $93.11 and a two-hundred day moving average price of $78.90. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.